Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
May 10 2021 - 8:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a
specialty biopharmaceutical company developing and commercializing
a diversified portfolio of pharmaceutical and diagnostic products,
today announced that Dr. Klaus Paulini, Chief Executive Officer of
Aeterna, will present at the Q2 Virtual Investor Summit on Monday,
May 17th at 8:45 AM ET.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A live video webcast of the presentation will be
accessible on the Events page in the Investors section of the
Company’s website (www.zentaris.com), and will be archived for 90
days following the event.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty
biopharmaceutical company developing and commercializing a
diversified portfolio of pharmaceutical and diagnostic products
focused on areas of significant unmet medical need. The Company's
lead product, macimorelin, is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). The Company is
leveraging the clinical success and compelling safety profile of
macimorelin to develop it for the diagnosis of childhood-onset
growth hormone deficiency (CGHD) in collaboration with Novo
Nordisk.
Aeterna Zentaris is dedicated to the development
of therapeutic assets and has recently taken steps to establish a
growing pipeline to address unmet medical needs across a number of
indications, including neuromyelitis optica spectrum disorder
(NMOSD), hypoparathyroidism and an undisclosed neurodegenerative
disease. Additionally, the Company is developing an oral
prophylactic bacterial vaccine against SARS-CoV-2, the virus that
causes COVID-19.
For more information, please visit
www.zentaris.com and connect with the Company on Twitter, LinkedIn
and Facebook.
Investor Contact:Jenene ThomasJTC TeamT (US):
+1 (833) 475-8247E: aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024